The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer--Genitourinary Group.

The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer--Genitourinary Group.

Item
http://www.wikidata.org/entity/Q44843703
Prognostic significance of pathological response after neoadjuvant chemotherapy or chemoradiation for locally advanced cervical carcinomaPooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancerSystemic, perioperative management of muscle-invasive bladder cancer and future horizons.The Role of Neoadjuvant Trials in Drug Development for Solid Tumors.Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guidelineRadiation-sparing managements for cervical cancer: a developing countries perspective.Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder.Clinical significance of DNA ploidy and S-phase fraction and their relation to p53 protein, c-erbB-2 protein and HCG in operable muscle-invasive bladder cancer.Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting.Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cellsTreatment Response Assessment for Bladder Cancer on CT Based on Computerized Volume Analysis, World Health Organization Criteria, and RECIST.A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experienceClinical states model for biomarkers in bladder cancerCirculating Tumor Cells as Potential Biomarkers in Bladder Cancer.Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer.Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy.Negative p53/positive p21 immunostaining is a predictor of favorable response to chemotherapy in patients with locally advanced bladder cancer.
P2860

The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer--Genitourinary Group.

Item
http://www.wikidata.org/entity/Q44843703
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh-hant
name
The prognostic value of the pa ...... f Cancer--Genitourinary Group.
@en
The prognostic value of the pa ...... f Cancer--Genitourinary Group.
@nl
type
label
The prognostic value of the pa ...... f Cancer--Genitourinary Group.
@en
The prognostic value of the pa ...... f Cancer--Genitourinary Group.
@nl
prefLabel
The prognostic value of the pa ...... f Cancer--Genitourinary Group.
@en
The prognostic value of the pa ...... f Cancer--Genitourinary Group.
@nl
P1433
P1476
P2093
P304
P31
P407
P433
P478
P577
P698
P921
P1433
P1476
The prognostic value of the pa ...... f Cancer--Genitourinary Group.
@en
P2093
P304
P31
P407
P433
P478
P577
P698
P921